Tovorafenib for children and young adults with high-grade glioma, including DIPG
Original title: Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug is still being tested in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether a drug called tovorafenib can help people with a newly found fast-growing brain tumor live longer.
Who this trial is for. This trial is for children and young adults who were just diagnosed with a high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary, including DIPG, and whose tumor has certain genetic changes in what is called the MAPK pathway. It is testing a drug called tovorafenib.
Where it stands. This trial has not reported any results. It is looking at whether tovorafenib helps these patients live longer. That answer is not in yet.
What this means, and what it doesn't
What it could mean: If you or your child match what this trial is looking for, you could ask your care team about it. They know your situation and can say whether it is worth looking into. The trial team decides who can join.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, July 31, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.